Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum DSM 15312 + lactobacillus paracasei DSM 13434
- Development stage
- Unknown
- Lead developer
- Probi
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a **combination of two probiotic bacterial strains**—Lactobacillus plantarum DSM 15312 and Lactobacillus paracasei DSM 13434—both of which are lactic acid bacteria with well-characterized immunomodulatory effects. The combination has been studied for its ability to modulate immune responses, most notably by increasing regulatory T cell (Treg) frequency and anti-inflammatory cytokines (IL-10, TGF-β), and by reducing pro-inflammatory cytokines such as IFN-γ and IL-17. Clinical and preclinical studies have evaluated this probiotic mix for the management of autoimmune conditions such as multiple sclerosis and for prevention/treatment of respiratory tract infections (e.g., the common cold). Its proposed mechanism is oral modulation of gut-immune interactions via cytokine induction and regulatory cell promotion, leading to systemic anti-inflammatory and immunoregulatory effects[1][2][5][7].
- Brand names
- Probi Defendum
- Other names
- lactobacillus plantarum HEAL 9 + lactobacillus paracasei 8700:2
Beyond the preview
Go deeper on lactobacillus plantarum DSM 15312 + lactobacillus paracasei DSM 13434.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum DSM 15312 + lactobacillus paracasei DSM 13434.